BR0012136A - Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos - Google Patents

Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos

Info

Publication number
BR0012136A
BR0012136A BR0012136-3A BR0012136A BR0012136A BR 0012136 A BR0012136 A BR 0012136A BR 0012136 A BR0012136 A BR 0012136A BR 0012136 A BR0012136 A BR 0012136A
Authority
BR
Brazil
Prior art keywords
methods
suffering
human
highly selective
compositions
Prior art date
Application number
BR0012136-3A
Other languages
English (en)
Inventor
Erik H F Wong
Saeeduddin Ahmed
Robert Clyde Marshall
Robert Mcarthur
Duncan P Taylor
Lars Birgerson
Pasquare Cetera
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0012136(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0012136A publication Critical patent/BR0012136A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"INIBIDORES DE REABSORçãO DE NOREPINEFRINA ALTAMENTE SELETIVOS E MéTODOS DE USO DOS MESMOS". Métodos e composições para o tratamento de seres humanos que sofrem ou de prevenção para um ser humano que sofre de uma doença psiquiátrica, um distúrbio, ou de uma condição onde a inibição da reabsorção de norepinefrina é um benefício, são mostrados. As composições compreendem um composto que tem uma seletividade farmacológica de serotonina ( K~ i~ ) / norepinefrina (K~ i~ ) de pelo menos cerca de 5000. Os exemplos desses compostos incluem reboxetina e, mais preferencialmente, um enantiómero de reboxetina oticamente pura ( S, S ). Os métodos, geralmente, incluem a administração de uma quantidade terapêutica dessas composições. Também são mostradas preparações de um medicamento a partir da composição, e usos da composição em uma fabricação do medicamento, para o tratamento de um ser humano que sofre, ou para a prevenção para um ser humano que sofre de uma doença fisiológica ou psiquiátrica, de um distúrbio, ou de uma condição.
BR0012136-3A 1999-07-01 2000-06-22 Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos BR0012136A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13
PCT/US2000/017256 WO2001001973A2 (en) 1999-07-01 2000-06-22 Highly selective norepinephrine reuptake inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
BR0012136A true BR0012136A (pt) 2002-06-11

Family

ID=27495506

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012136-3A BR0012136A (pt) 1999-07-01 2000-06-22 Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos

Country Status (31)

Country Link
US (18) US6465458B1 (pt)
EP (3) EP2090312A1 (pt)
JP (3) JP2003503450A (pt)
KR (5) KR100704319B1 (pt)
CN (5) CN1660109A (pt)
AR (1) AR035158A1 (pt)
AT (9) ATE319453T1 (pt)
AU (2) AU771258B2 (pt)
BR (1) BR0012136A (pt)
CA (2) CA2643231A1 (pt)
CL (3) CL2008002867A1 (pt)
CO (1) CO5190662A1 (pt)
CZ (1) CZ299847B6 (pt)
DE (9) DE60019473T2 (pt)
DK (4) DK1196172T3 (pt)
EA (6) EA008381B1 (pt)
ES (9) ES2246487T3 (pt)
GE (1) GEP20094798B (pt)
HK (2) HK1049630A1 (pt)
HU (1) HUP0201623A3 (pt)
IL (3) IL147246A0 (pt)
MX (1) MXPA02000562A (pt)
MY (1) MY137348A (pt)
NO (4) NO20016406L (pt)
NZ (2) NZ515885A (pt)
PE (1) PE20010684A1 (pt)
PL (1) PL196996B1 (pt)
PT (5) PT1459748E (pt)
SK (5) SK286104B6 (pt)
TW (9) TWI293250B (pt)
WO (1) WO2001001973A2 (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
ES2287039T3 (es) * 1999-12-01 2007-12-16 Ucb, S.A. Un derivado de pirrolidinacetamida para el tratamiento de dolor cronico o neuropatico.
WO2001087308A1 (en) * 2000-04-21 2001-11-22 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
WO2001081343A2 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
EA200300567A1 (ru) * 2000-11-15 2004-10-28 Эли Лилли Энд Компани Лечение состояний тревоги
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
PT1397145E (pt) * 2001-06-19 2006-10-31 Norbert Muller Utilizacao de inibidores da cox-2 para o tratamento de esquizofrenia ou de disturbios de tiques
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CA2466649A1 (en) * 2001-11-30 2003-06-12 Eli Lilly & Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
CA2467802A1 (en) * 2001-12-11 2003-06-19 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
EP2301537A1 (en) 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
WO2003101453A1 (en) * 2002-05-30 2003-12-11 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
BR0311878A (pt) * 2002-06-17 2005-04-05 Pharmacia Italia Spa Sais farmacêuticos de reboxetina
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
WO2004016272A1 (en) * 2002-08-14 2004-02-26 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
WO2004017977A2 (en) 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
EP1546123B1 (en) 2002-08-23 2006-05-31 Eli Lilly And Company Benzyl morpholine derivatives
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US20040106681A1 (en) * 2002-10-03 2004-06-03 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
EP2286817A3 (en) * 2003-01-13 2011-06-15 Edusa Pharmaceuticals, Inc Method of treating functional bowel disorders
ES2290741T3 (es) * 2003-04-04 2008-02-16 Dynogen Pharmaceuticals Inc. Metodo de tratamiento de trastornos del tracto urinario inferior.
US7375111B2 (en) 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
EP1663398B1 (en) * 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
ES2307071T3 (es) * 2003-12-12 2008-11-16 Eli Lilly And Company Inhibidores selectivos de la recaptacion de norepinefrina para el tratamiento de sofocos.
WO2005066144A1 (en) * 2003-12-23 2005-07-21 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GEP20084550B (en) 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
KR20070029740A (ko) * 2004-06-09 2007-03-14 화이자 인코포레이티드 통증 치료를 위한 레복세틴의 용도
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
RS52057B2 (sr) 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
JP2008514689A (ja) * 2004-10-01 2008-05-08 ニューロキュア リミテッド Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008003028A2 (en) * 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
EP2468271B1 (en) 2007-03-09 2014-07-16 Chelsea Therapeutics, Inc. Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101720186A (zh) * 2007-04-30 2010-06-02 阿得罗公司 (-)-e-10-oh-nt组合物及其合成与使用的方法
EP2167066B1 (en) * 2007-05-07 2013-06-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
EP2454234B1 (en) 2009-07-13 2018-04-11 Theravance Biopharma R&D IP, LLC 3-phenoxymethylpyrrolidine compounds
EP2456436B1 (en) * 2009-07-21 2014-06-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CA2811641A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
CR20220247A (es) * 2019-12-03 2022-08-18 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ZA921292B (en) 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5945416A (en) 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
AU2587297A (en) 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
ATE172117T1 (de) 1996-11-27 1998-10-15 Pfleger R Chem Fab Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
JP2002503224A (ja) 1997-04-11 2002-01-29 エリ リリー アンド カンパニー 疼痛を処置するための組成物
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
JP2001520195A (ja) 1997-10-17 2001-10-30 イーライ・リリー・アンド・カンパニー 医薬の増強
CA2634698A1 (en) * 1998-04-09 1999-10-21 Pharmacia & Upjohn Company New treatments for nervous disorders
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
WO1999058130A1 (en) * 1998-05-08 1999-11-18 Pharmacia & Upjohn Company New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
MXPA00012767A (es) 1998-06-29 2002-08-09 Pharmaceuticals Applic Asociat Metodos y composiciones transdermicas para el alivio del dolor.
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
CN1660435A (zh) 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
KR100704319B1 (ko) 2007-04-09
US20030040464A1 (en) 2003-02-27
EA200200111A1 (ru) 2002-06-27
SK19382001A3 (sk) 2002-07-02
CN1660108A (zh) 2005-08-31
CL2008002868A1 (es) 2009-01-09
US7317011B2 (en) 2008-01-08
EP1196172B1 (en) 2006-03-15
CN1660109A (zh) 2005-08-31
US20060135520A1 (en) 2006-06-22
DK1632234T3 (da) 2007-09-17
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
HK1076723A1 (en) 2006-01-27
TWI245631B (en) 2005-12-21
US6465458B1 (en) 2002-10-15
SK286104B6 (sk) 2008-03-05
US20060264436A1 (en) 2006-11-23
ES2258010T3 (es) 2006-08-16
SK286667B6 (sk) 2009-03-05
TWI294779B (en) 2008-03-21
DE60035232T2 (de) 2008-02-14
CN1289090C (zh) 2006-12-13
EP2087892A2 (en) 2009-08-12
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
ATE292971T1 (de) 2005-04-15
DK1459750T3 (da) 2005-08-15
EA011094B1 (ru) 2008-12-30
ATE305307T1 (de) 2005-10-15
PE20010684A1 (es) 2001-06-24
ES2246485T3 (es) 2006-02-16
KR100717660B1 (ko) 2007-05-15
HUP0201623A2 (en) 2002-09-28
ATE319453T1 (de) 2006-03-15
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (en) 2002-04-17
IL187512A0 (en) 2008-06-05
IL147246A0 (en) 2002-08-14
JP2003503450A (ja) 2003-01-28
CZ299847B6 (cs) 2008-12-10
EA005029B1 (ru) 2004-10-28
US6642235B2 (en) 2003-11-04
MY137348A (en) 2009-01-30
ES2246488T3 (es) 2006-02-16
EP2090312A1 (en) 2009-08-19
WO2001001973A2 (en) 2001-01-11
ES2242175T3 (es) 2005-11-01
US7241762B2 (en) 2007-07-10
SK286668B6 (sk) 2009-03-05
KR100935277B1 (ko) 2010-01-06
CL2008002867A1 (es) 2009-01-09
AU2004202096A1 (en) 2004-06-10
AU5633700A (en) 2001-01-22
CN1379672A (zh) 2002-11-13
DE60022692D1 (de) 2005-10-20
DE60020613T2 (de) 2006-03-16
US7723334B2 (en) 2010-05-25
NZ515885A (en) 2004-08-27
EA200801805A1 (ru) 2008-12-30
DE60022917D1 (de) 2006-02-09
DE60035232D1 (de) 2007-07-26
US6703389B2 (en) 2004-03-09
ES2258251T3 (es) 2006-08-16
US20090247528A1 (en) 2009-10-01
TW200607511A (en) 2006-03-01
DE60023043T2 (de) 2006-06-14
JP2006321815A (ja) 2006-11-30
EP2087892A3 (en) 2009-09-30
ATE304358T1 (de) 2005-09-15
NO20091159L (no) 2002-02-19
US20020128173A1 (en) 2002-09-12
GEP20094798B (en) 2009-10-26
US20080096890A1 (en) 2008-04-24
DE60026704D1 (de) 2006-05-11
KR20020015363A (ko) 2002-02-27
CA2375908C (en) 2006-05-30
US20080103146A1 (en) 2008-05-01
AR035158A1 (es) 2004-05-05
TW200920378A (en) 2009-05-16
ATE305306T1 (de) 2005-10-15
NO20091168L (no) 2002-02-19
IL187513A0 (en) 2008-06-05
TW200607512A (en) 2006-03-01
PT1632234E (pt) 2007-07-09
CN1205935C (zh) 2005-06-15
US20020107249A1 (en) 2002-08-08
US20060142289A1 (en) 2006-06-29
EA200801806A1 (ru) 2008-12-30
DE60019473D1 (de) 2005-05-19
DE60022916T2 (de) 2006-07-06
DE60022692T2 (de) 2006-06-22
TW200607509A (en) 2006-03-01
HUP0201623A3 (en) 2004-12-28
ES2239311T3 (es) 2005-09-16
TW200914027A (en) 2009-04-01
US20040147614A1 (en) 2004-07-29
DE60026704T2 (de) 2006-10-19
AU2004202096B2 (en) 2005-10-20
CN1660110A (zh) 2005-08-31
NO20016406L (no) 2002-02-19
ATE296634T1 (de) 2005-06-15
US6610690B2 (en) 2003-08-26
DE60020613D1 (de) 2005-07-07
ATE305788T1 (de) 2005-10-15
NO20016406D0 (no) 2001-12-28
US6987107B2 (en) 2006-01-17
US7338953B2 (en) 2008-03-04
ES2247572T3 (es) 2006-03-01
TW200407146A (en) 2004-05-16
EA200400589A1 (ru) 2004-12-30
TWI298255B (en) 2008-07-01
US20060128705A1 (en) 2006-06-15
DE60019473T2 (de) 2006-02-23
AU771258B2 (en) 2004-03-18
SK286669B6 (sk) 2009-03-05
NO20091158L (no) 2002-02-19
PL352252A1 (en) 2003-08-11
DE60023043D1 (de) 2006-02-16
MXPA02000562A (es) 2002-07-02
ATE320257T1 (de) 2006-04-15
SK286864B6 (sk) 2009-06-05
DK1459749T3 (da) 2006-01-09
KR20090087135A (ko) 2009-08-14
EA200501496A1 (ru) 2006-06-30
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
PL196996B1 (pl) 2008-02-29
JP2006143749A (ja) 2006-06-08
PT1196172E (pt) 2006-05-31
TW200607510A (en) 2006-03-01
ES2285645T3 (es) 2007-11-16
EA008381B1 (ru) 2007-04-27
US20080103147A1 (en) 2008-05-01
CA2643231A1 (en) 2001-01-11
PT1459750E (pt) 2005-08-31
CZ20014625A3 (cs) 2002-08-14
KR20050053799A (ko) 2005-06-08
WO2001001973A8 (en) 2001-05-17
KR100948757B1 (ko) 2010-03-23
CN1660111A (zh) 2005-08-31
DE60022917T2 (de) 2006-06-29
NZ533243A (en) 2005-12-23
US20020061910A1 (en) 2002-05-23
US7276503B2 (en) 2007-10-02
US20080103145A1 (en) 2008-05-01
HK1049630A1 (en) 2003-05-23
PT1459751E (pt) 2005-11-30
TWI298254B (en) 2008-07-01
CL2008002866A1 (es) 2009-01-09
EA006652B1 (ru) 2006-02-24
WO2001001973A3 (en) 2002-01-17
KR20060099544A (ko) 2006-09-19
ES2246487T3 (es) 2006-02-16
DE60022916D1 (de) 2006-02-09
TWI293250B (en) 2008-02-11
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
KR20090087134A (ko) 2009-08-14
US20060135521A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0110420A (pt) Agonistas muscarìnicos
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BR9909277A (pt) Compostos com atividade em receptores muscarìnicos
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
AU645023B2 (en) Compositions and method for treating painful, inflammatory or allergic disorders
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
BR0213248A (pt) Formulação farmacêutica, dose farmacêutica, dispersão sólida de um polìmero entérico, métodos para o tratamento de cãncer de próstata e/ou para a redução do risco de cancer de próstata em um paciente, para aumentara biodisponibilidade e a estabilidade em armazenamento de 4'-ciano-alfa',alfa',alfa' -trifluoro-3-(4-fluorofenilsilfonil)-2-hidróxi-2-metil propiono-m-toluidida, e para a preparação de uma formulação farmacêutica, e, usos de 4'-ciano-alfa',alfa',alfa'-trifluoro-3-(4-fluorofenilsu lfonil -2-hidróxi-2-metilpropiono-m-toluidida e de um polìmero entérico
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
ATE81462T1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0212167A (pt) Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.